Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Treatment of Congenital Hyperinsulinism, an Orphan Disease

Austin, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for diabetes and other diseases, was awarded a Small Business Innovation Research (SBIR) Phase I grant for $485,403 to advance the company's room-temperature stable, non-aqueous glucagon formulation for the treatment of Congenital Hyperinsulinism (CH). The funding represents the initial installment of a Phase I-II Fast Track SBIR grant, with the potential for a total award of approximately $2 million with Phase II funding. The grant was awarded on March 24 by the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), an institute of the National Institutes of Health (NIH) which funds research on diabetes and other metabolic diseases. 

Grant funding will support drug supplies manufacturing, preclinical studies, regulatory development, and a foundational clinical trial. The clinical trial will be conducted at two hospitals in the US that are renowned treatment centers for patients with CH.  Studies at Cook Children’s Medical Center in Fort Worth, TX, will be led by co-Principal Investigator, Dr. Paul Thornton, a pediatric endocrinologist and Medical Director of Cook Children’s Endocrine and Diabetes Program and Congenital Hyperinsulinism Center. Studies at The Children’s Hospital of Philadelphia, in Philadelphia, PA will be led by Dr. Diva D. De Leon-Crutchlow, a pediatric endocrinologist and Director of the Congenital Hyperinsulinism Center.  For patients with CH, the pancreas secretion of insulin is not appropriately regulated, which results in severe-persistent hypoglycemia (low blood sugar) that can cause brain damage, blindness and be life-threatening.  The project aims to use a glucagon infusion pump to maintain blood glucose levels at near normal levels and thus prevent hypoglycemia, without the requirement of an intravenous infusion that is often used in the hospital to treat these children.  Once patients are stabilized in the hospital, the ultimate goal of this program would be to use the glucagon pump to enable discharge of the patient into an outpatient setting under care of the parents and/or nurse. 

 “Working with the NIDDK and Drs. Thornton and De Leon-Crutchlow in the development of continuous subcutaneous infusion of Xeris glucagon administered through a pump will allow us to potentially develop an innovative product for prevention of hypoglycemia in this patient population” said Dr. Steven Prestrelski, Chief Scientific Officer for Xeris Pharmaceuticals and Principal Investigator. “This is a significant unmet medical need and the SBIR funding will help advance our novel formulation and delivery system for glucagon.”

Grant Number: 1R44DK105691-01
Project Name: CSI Glucagon for Treatment of Congenital Hyperinsulinism

About Congenital Hyperinsulinism
Congenital hyperinsulinism (CH) is the most frequent cause of severe, persistent hypoglycemia (very low blood sugar) in newborn babies and children.  It occurs in approximately 1/25,000 to1/50,000 births in the United States. About 60% of neonates with CH develop hypoglycemia during the first month of life. An additional 30% will be diagnosed later in the first year and the remainder after that. Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, a hormone that helps control blood sugar levels. Infants and children with CH have severe-persistent hypoglycemia. In infants and young children, these episodes are characterized by a lack of energy, irritability, difficulty feeding and may lead to seizures and breathing difficulties. Repeated episodes of low blood sugar can result in permanent seizure disorder, learning disabilities, cerebral palsy, blindness or even death.

About Glucagon
Glucagon is a metabolic hormone secreted by the pancreas that raises blood glucose levels by causing the liver to rapidly convert glycogen (the stored form of glucose) into glucose, which is then released into the bloodstream. Glucagon and insulin are two critical hormones in a glycemic control system that keeps blood glucose at the right level in healthy individuals. In patients with CH, genetic defects cause the pancreas to continuously overexpress insulin. More commonly, glucagon is associated with people with diabetes who are dependent on insulin, where this control system is disrupted and insulin must be injected prior to meals to avoid high levels of blood glucose (hyperglycemia). The opposite effect of low blood glucose (hypoglycemia) is also prevalent in this population, resulting from too much insulin or exercise. If untreated, this leads to severe hypoglycemia, a serious condition and can cause seizures, coma, potential brain injury and, death. Xeris’ proprietary glucagon formulation has the potential to provide the first soluble, room temperature stable, pump-delivered glucagon for continuous infusion to prevent severe-persistent hypoglycemia associated with CH.

About Xeris Pharmaceuticals, Inc.
Xeris is an Austin, Texas-based, specialty biopharmaceutical company developing improved and differentiated, injectable therapeutics for multiple indications including diabetes. The company's proprietary non-aqueous formulation technologies allow for the delivery of highly concentrated, non-aqueous, ready-to-inject suspension and solution formulations of peptides, proteins, antibodies and small molecules. Xeris' proprietary formulation approach offers distinct advantages over existing products and formulations including: up to 1000-fold lower injection volumes, eliminating the need for reconstitution and refrigeration, with extended room temperature shelf-life stability, all of which can lead to products that are easier to use by patients, caregivers, health practitioners, and that can reduce costs for payers and the healthcare system. For more information, please visit the Xeris website at: www.xerispharma.com





Michelle Bybee Xeris Pharmaceuticals, Inc. (512)478-2676 mbybee@xerispharma.com www.xerispharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 61

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 236

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 114

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 79

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 102

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 206

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 39

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 94

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocean Power Technologies Enhances Market Reach with New Partnership

Updated Category News Views 124

Expanding Horizons in Latin America Ocean Power Technologies, Inc. (NYSE American: OPTT), a pioneer in low-carbon marine power solutions, has taken a significant step in expanding its operational footprint by signing a reseller agreement in Latin America. This significant partnership primarily targets the offshore and maritime sectors in Mexico. A New Partnership for...

Continue Reading
Aktsiaselts Infortar's Strategic Move in the Polish Energy Sector

Updated Category News Views 121

Aktsiaselts Infortar Expands Into Poland's Energy Market Aktsiaselts Infortar, through its wholly owned subsidiary AS Eesti Gaas, has taken a significant step in its growth strategy by acquiring 100% of EWE Polska sp. z o.o., an important player in the Polish energy sector. This strategic acquisition enables Infortar to broaden its operational footprint beyond the...

Continue Reading
Exciting Insights Await at Can-Fite's Live Investor Webinar

Updated Category News Views 151

Join Can-Fite BioPharma's Informative Live Investor Webinar Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is thrilled to announce an exclusive live investor webinar aimed at sharing vital insights into their innovative drug pipeline. This engaging session will take place on a Tuesday afternoon, providing an excellent opportunity for investors and stakeholders...

Continue Reading
Ajinomoto Co. Partners with LabCentral to Boost Biotech Innovation

Updated Category News Views 365

Ajinomoto Co., Inc. Enhances Biotech Innovation Ajinomoto Co., Inc., a prominent player in biotechnology and food innovation, recently unveiled its full-scale support for LabCentral, a distinguished platform for startups in the biosciences sector. This initiative reaffirms the Ajinomoto Group's dedication to innovation and collaborative growth within an ever-evolving...

Continue Reading
ATI Physical Therapy's Strategic Shift to Private Ownership

Updated Category News Views 610

ATI Physical Therapy Shifts to Private Ownership ATI Physical Therapy, Inc. (OTC: ATIP), known for its outstanding outpatient physical therapy and rehabilitation services, has made a significant transition. In a recent announcement, the company disclosed its evolution from public to private ownership, led by a consortium of existing shareholders including Knighthead...

Continue Reading